3D Medicines, Chinese leading cancer-targeted theranostic platform company, has raised ¥670 million in a new funding round recently. The round was led by the State-Controlled Venture Capital Fund mainly sponsored by China Reform Holdings Corporation LTD.
Zensun Sci & Tech (871392.OC), a leading innovative drug developer in China, announced an impressive RMB 507 million financing round yesterday, led by SDIC Venture Capital Management Co., Ltd., with a host of new backers including Tianfeng Tianrui Investm
Cygnus Biosciences (Beijing) Co., Ltd., a leading domestic company focusing on developing local High-Throughput DNA sequencing platform, announced its Series B financing of RMB 130 million which was jointly led by Oriental Yirui (Shanghai) Fund and the Zh
Arrail Dental Group, China's leading high-end dental care provider with close to a hundred clinics and dental hospitals, announced today that it had completed a $90 million Series D financing. The round was led by Goldman Sachs Group and Hillhouse Capita
Coyote Bioscience, a leading molecular diagnosis company in China, announced today that it had completed Series B financing. The round was led by Northern Light Ventures, with participation from SAIF Asia and Legend Star.